Tempest Therapeutics, Inc.
General ticker "TPST" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $208.4M (TTM average)
Tempest Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -3.8%.
Estimated limits based on current volatility of 3.6%: low 2.19$, high 2.35$
Factors to consider:
- Total employees count: 17 (-10.5%) as of 2023
- Top business risk factors: Insufficient funding, Regulatory and compliance, Manufacturing risks, Product liability, Economic downturns and volatility
- Price in estimated range
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [3.28$, 13.49$]
- 2025-12-31 to 2026-12-31 estimated range: [1.64$, 7.45$]
Financial Metrics affecting the TPST estimates:
- Negative: with PPE of -0.5 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -11.35 <= 0.01
- Negative: negative Net income
- Positive: 42.68 < Shareholder equity ratio, % of 46.10 <= 64.29
- Negative: Industry earnings per price (median), % of -15.81 <= 0
- Positive: Investing cash flow per share per price, % of -0.15 > -0.63
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term TPST quotes
Long-term TPST plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $34.64MM | $29.16MM | $42.03MM |
| Operating Income | $-34.64MM | $-29.16MM | $-42.03MM |
| Non-Operating Income | $-1.07MM | $-0.33MM | $0.18MM |
| Interest Expense | $1.62MM | $1.45MM | $1.32MM |
| R&D Expense | $22.53MM | $17.50MM | $28.48MM |
| Income(Loss) | $-35.71MM | $-29.49MM | $-41.84MM |
| Profit(Loss)* | $-35.71MM | $-29.49MM | $-41.84MM |
| Stockholders Equity | $18.11MM | $26.77MM | $19.13MM |
| Assets | $46.09MM | $51.60MM | $41.49MM |
| Operating Cash Flow | $-31.07MM | $-27.36MM | $-33.03MM |
| Capital expenditure | $0.56MM | $0.17MM | $0.43MM |
| Investing Cash Flow | $-0.56MM | $-0.17MM | $-0.43MM |
| Financing Cash Flow | $11.40MM | $35.60MM | $24.50MM |
| Earnings Per Share** | $-40.21 | $-1.91 | $-1.50 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.